A liquid biopsy is fast ahead traction as a supplement or alternate to doing a tissue biopsy for applications in procreative health, cancer, and transplant medicine. The liquid biopsy techniques agree the physicians to comprehend the critical nature of the disease after the finding and screening procedure. The main biomarker kinds used in liquid biopsy contain circulating cell-free nucleic acids. Extracellular vesicles are a varied class of lipid-bound elements shed by any cell in the body in pathological and physiological conditions. Microarray technology has been widely used in cancer research for more than a period. Droplet Digital PCR agrees for the detection of target sequences which are contemporary in the very low background against other sequences present at high concentrations. Proteomics platforms include Mass Spectrometry and biochips. Deficiency of consensus on Standard Operating Measures and poor compensation structures are some of the main factors hindering the global liquid biopsy market. The compensation and treatment monitoring for liquid biopsy is limited, and it is achieved in a few laboratories. The poor reimbursement system is a important restraint which restricts the individuals to go for cancer detection tests and affects cancer biomarkers market negatively.
The global Liquid Biopsy market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Liquid Biopsy market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Mdxhealth SA, Genomic Health, Inc., Raindance Technologies, Inc, Thermo Fisher Scientific Inc., Illumina, Inc., Biocept, Inc, Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc, and others are among the major players in the global Liquid Biopsy market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Liquid Biopsy Market has been segmented as below:
Liquid Biopsy Market, By Application
Liquid Biopsy Market, By End User
Liquid Biopsy Market, By Clinical Application
Liquid Biopsy Market, By Product and Service
Liquid Biopsy Market, By Circulating Biomarker
Liquid Biopsy Market, By Technology
Liquid Biopsy Market, By Region
Liquid Biopsy Market, By Company
The report covers:
Report Scope:
The global Liquid Biopsy market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Liquid Biopsy market share. Major industry players with significant revenue share include Mdxhealth SA, Genomic Health, Inc., Raindance Technologies, Inc, Thermo Fisher Scientific Inc., Illumina, Inc., Biocept, Inc, Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc, and others.
Reasons to Buy this Report:
Some of the recent developments in Liquid Biopsy Market are as follows:
Mdxhealth SA
Genomic Health, Inc.
Customization
Customized report as per the requirement can be offered with appropriate recommendations.
Below are our New Reports :-
Connected Drug Delivery Devices Market
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach – Segmental Market Analysis
2.5.2 Top-Down Approach – Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter’s Five Force Analysis
5. Liquid Biopsy Market, By Application
5.1 Introduction
5.2 Non-Cancer Applications
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Cancer Applications
5.3.1 Market Overview
5.3.2 Market Size and Forecast
6. Liquid Biopsy Market, By End User
6.1 Introduction
6.2 Academic and Research Centers
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Hospitals and Physician Laboratories
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Reference Laboratories
6.4.1 Market Overview
6.4.2 Market Size and Forecast
6.5 Other End Users
6.5.1 Market Overview
6.5.2 Market Size and Forecast
7. Liquid Biopsy Market, By Clinical Application
7.1 Introduction
7.2 Early Cancer Screening
7.2.1 Market Overview
7.2.2 Market Size and Forecast
7.3 Recurrence Monitoring
7.3.1 Market Overview
7.3.2 Market Size and Forecast
7.4 Treatment Monitoring
7.4.1 Market Overview
7.4.2 Market Size and Forecast
7.5 Therapy Selection
7.5.1 Market Overview
7.5.2 Market Size and Forecast
8. Liquid Biopsy Market, By Product and Service
8.1 Introduction
8.2 Instruments
8.2.1 Market Overview
8.2.2 Market Size and Forecast
8.3 Services
8.3.1 Market Overview
8.3.2 Market Size and Forecast
8.4 Assay Kits
8.4.1 Market Overview
8.4.2 Market Size and Forecast
9. Liquid Biopsy Market, By Circulating Biomarker
9.1 Introduction
9.2 Extracellular Vesicles
9.2.1 Market Overview
9.2.2 Market Size and Forecast
9.3 Circulating Tumor Cells
9.3.1 Market Overview
9.3.2 Market Size and Forecast
9.4 Circulating Tumor Dna
9.4.1 Market Overview
9.4.2 Market Size and Forecast
9.5 Cell-Free Dna
9.5.1 Market Overview
9.5.2 Market Size and Forecast
9.6 Other Circulating Biomarkers
9.6.1 Market Overview
9.6.2 Market Size and Forecast
10. Liquid Biopsy Market, By Technology
10.1 Introduction
10.2 Single Gene Analysis Using Pcr Microarrays
10.2.1 Market Overview
10.2.2 Market Size and Forecast
10.3 Multi-Gene-Parallel Analysis Using Ngs
10.3.1 Market Overview
10.3.2 Market Size and Forecast
11. Liquid Biopsy Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 North America Liquid Biopsy, By Application
11.2.2 North America Liquid Biopsy, By End User
11.2.3 North America Liquid Biopsy, By Clinical Application
11.2.4 North America Liquid Biopsy, By Product and Service
11.2.5 North America Liquid Biopsy, By Circulating Biomarker
11.2.6 North America Liquid Biopsy, By Technology
11.3 Europe
11.3.1 Europe Liquid Biopsy, By Application
11.3.2 Europe Liquid Biopsy, By End User
11.3.3 Europe Liquid Biopsy, By Clinical Application
11.3.4 Europe Liquid Biopsy, By Product and Service
11.3.5 Europe Liquid Biopsy, By Circulating Biomarker
11.3.6 Europe Liquid Biopsy, By Technology
11.4 Asia-Pacific
11.4.1 Asia-Pacific Liquid Biopsy, By Application
11.4.2 Asia-Pacific Liquid Biopsy, By End User
11.4.3 Asia-Pacific Liquid Biopsy, By Clinical Application
11.4.4 Asia-Pacific Liquid Biopsy, By Product and Service
11.4.5 Asia-Pacific Liquid Biopsy, By Circulating Biomarker
11.4.6 Asia-Pacific Liquid Biopsy, By Technology
11.5 Rest of the World
11.5.1 Rest of the World Liquid Biopsy, By Application
11.5.2 Rest of the World Liquid Biopsy, By End User
11.5.3 Rest of the World Liquid Biopsy, By Clinical Application
11.5.4 Rest of the World Liquid Biopsy, By Product and Service
11.5.5 Rest of the World Liquid Biopsy, By Circulating Biomarker
11.5.6 Rest of the World Liquid Biopsy, By Technology
12. Competitive Insights
12.1 Key Insights
12.2 Company Market Share Analysis
12.3 Strategic Outlook
12.3.1 Mergers & Acquisitions
12.3.2 New Product Development
12.3.3 Portfolio/Production Capacity Expansions
12.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
12.3.5 Others
13. Company Profiles
13.1 Mdxhealth SA
13.1.1 Company Overview
13.1.2 Product/Service Landscape
13.1.3 Financial Overview
13.1.4 Recent Developments
13.2 Genomic Health, Inc.
13.2.1 Company Overview
13.2.2 Product/Service Landscape
13.2.3 Financial Overview
13.2.4 Recent Developments
13.3 Raindance Technologies, Inc
13.3.1 Company Overview
13.3.2 Product/Service Landscape
13.3.3 Financial Overview
13.3.4 Recent Developments
13.4 Thermo Fisher Scientific Inc.
13.4.1 Company Overview
13.4.2 Product/Service Landscape
13.4.3 Financial Overview
13.4.4 Recent Developments
13.5 Illumina, Inc.
13.5.1 Company Overview
13.5.2 Product/Service Landscape
13.5.3 Financial Overview
13.5.4 Recent Developments
13.6 Biocept, Inc
13.6.1 Company Overview
13.6.2 Product/Service Landscape
13.6.3 Financial Overview
13.6.4 Recent Developments
13.7 Qiagen N.V.
13.7.1 Company Overview
13.7.2 Product/Service Landscape
13.7.3 Financial Overview
13.7.4 Recent Developments
13.8 Roche Diagnostics
13.8.1 Company Overview
13.8.2 Product/Service Landscape
13.8.3 Financial Overview
13.8.4 Recent Developments
13.9 Bio-Rad Laboratories, Inc.
13.9.1 Company Overview
13.9.2 Product/Service Landscape
13.9.3 Financial Overview
13.9.4 Recent Developments
13.10 Myriad Genetics, Inc
13.10.1 Company Overview
13.10.2 Product/Service Landscape
13.10.3 Financial Overview
13.10.4 Recent Developments
13.11 Menarini-Silicon Biosystems
13.11.1 Company Overview
13.11.2 Product/Service Landscape
13.11.3 Financial Overview
13.11.4 Recent Developments
13.12 Trovagene, Inc.
13.12.1 Company Overview
13.12.2 Product/Service Landscape
13.12.3 Financial Overview
13.12.4 Recent Developments
13.13 Guardant Health, Inc
13.13.1 Company Overview
13.13.2 Product/Service Landscape
13.13.3 Financial Overview
13.13.4 Recent Developments
The Liquid Biopsy Market has been segmented as below:
Liquid Biopsy Market, By Application
Liquid Biopsy Market, By End User
Liquid Biopsy Market, By Clinical Application
Liquid Biopsy Market, By Product and Service
Liquid Biopsy Market, By Circulating Biomarker
Liquid Biopsy Market, By Technology
Liquid Biopsy Market, By Region
Liquid Biopsy Market, By Company
